Publicaciones en colaboración con investigadores/as de University of Toronto (4)

2021

  1. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 18, pp. 1959-1970

2011

  1. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs

    Journal of Clinical Oncology, Vol. 29, Núm. 18, pp. 2543-2549